Polymyxins: Older antibiotics for a new threat

Connecticut Medicine

Volumn 70, Issue 1, 2006, Pages 25-28

  Lee, Su Young ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; COLISTIN; POLYMYXIN; POLYMYXIN A; POLYMYXIN B; POLYMYXIN C; POLYMYXIN D1; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ATAXIA; CIRCUMORAL PARESTHESIA; DIZZINESS; DRUG INDICATION; DRUG MECHANISM; HUMAN; KIDNEY FUNCTION; NEPHROTOXICITY; NEUROTOXICITY; REVIEW; WEAKNESS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; POLYMYXINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 30344464441     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33:960-7.
2. Bedford Laboratories: Polymixin B for infection package insert. Bedford (OH): Bedford Laboratories; 2001.
3. Pharma-Tec, Inc.: Colistimethate for infection package insert. Huntington (NY): PharmaTec, Inc.; 1998.
4. Catchpole CR, Andrews JM, Brenwald N, Wise R: A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39:255-60.
5. Linden K. Colistin: An old drug with a new future? Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, October 30-November 2, 2005.
6. Nakamura T, Ushiyama C, Suzuki Y, et al: Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect 2003; 53:58-63.
7. Gales AC, Reis AO, Jones RN: Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39:183-90.
8. Gales AC, Jones RN, Sader HS: Assessment of the antimicrobial activity of polymyxin B against contemporary gram-negative bacilli isolated in Latin America: Results of SENTRY antimicrobial surveillance program-2001. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, USA, September 27-30, 2002.
9. CLSI: Performance standards for antimicrobial susceptibility testing; 15th informational supplement. Vol. 25 (ed 15th). Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2005.
10. Livermore DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002; 34:634-40.
11. Urban C, Segal-Maurer S, Rahal JJ: Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268-74.
12. Monarch Pharmaceuticals, Inc. Coly-Mycin Mpackage insert. Bristol (TN); Monarch Pharmaceuticals, Inc.; 2002.
13. Hermsen ED, Sullivan CJ, Rotschafer JC: Polymyxins: Pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin N Am 2003; 17:545-62.
14. Sobieszczyk ME, Furuya EY, Hay CM, et al: Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54:566-9.
15. Michalopoulos A, Kasiakou SK, Mastora Z, et al: Aerosolized colistin for the treatment of nosocomial pneumoniadue to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9:R53-9.
16. Hodson ME, Gallagher CG, Govan JR: A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-64.
17. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM: Toxicity of colistin in cystic fibrosis patients. DICP 1991; 25:1168-70.
18. Reed MD, Stern RC, O'Riordan MA, Blumer JL: The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41:645-54.
19. Gunderson BW, Ibrahim KH, Hovde LB, et al: Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:905-9.
20. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, et al: Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002;21:212-214.
21. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
22. Linden PK, Kusne S, Coley K, et al: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154-60.
23. Garrod LP, O'Grady F: Peptide antibiotics. In: Grrod LP, O'Grady F, eds. Antibiotic and Chemotherapy. Baltimore: Williams & Wilins; 1971:182-201.
24. Stein A, Raoult D: Colistin: An antimicrobial for the 21st century? Clin Infect Dis 2002; 35:901-2.
25. Kollef MH: An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Clin Infect Dis 2003; 36:1119-21.
26. Jones A, Elphick H, Pettitt E, et al: Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase. Eur Respir J 2002; 19:1136-41.
27. Marcos P, Calizaya M, Marin M, et al: Toxicity of colistin: Much ado about nothing? Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17-20, 2000.
28. Ouderkirk JP, Nord JA, Turett GS, Kislak JW: Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003; 47:2659-62.
29. Levin AS, Barone AA, Penco J, et al: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
30. Markou N, Apostolakos H, Koumoudiou C, et al: Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78-83.
31. Karabinis A, Paramythiotou E, Mylona-Petropoulou D, et al: Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004; 38:e7-9.